AKBA | tickerfilter.com

Fundamental analysis

26%

Profitability 25%

Dept financing 25%

Liquidity 21%

Performance 28%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.54%

1 Month

-9.27%

3 Months

39.85%

6 Months

102.17%

1 Year

56.30%

2 Year

335.90%

Key data

Stock price

$1.92

P/E Ratio

-7.93

DAY RANGE

$1.86 - $1.92

EPS

-$0.21

52 WEEK RANGE

$0.93 - $2.48

52 WEEK CHANGE

$45.31

MARKET CAP

325.947 M

YIELD

N/A

SHARES OUTSTANDING

210.288 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

1.49

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,233,020

AVERAGE 30 VOLUME

$2,226,175

Company detail

CEO: John P. Butler
Region: US
Website: akebia.com
Employees: 430
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Akebia Therapeutics, Inc. focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients on dialysis.

AKBA - Akebia Therapeutics, Inc.